Unlocking the Potential of Ribosomal Protein L23a Pseudogene 87 as a Drug Target or Biomarker

Target Name: RPL23AP87

NCBI ID: G388574

RPL23AP87

Other Name(s): Ribosomal protein L23a pseudogene 87 | ribosomal protein L23a pseudogene 87

Unlocking the Potential of Ribosomal Protein L23a Pseudogene 87 as a Drug Target or Biomarker

Ribosomal protein L23a pseudogene 87 (RPL23AP87) is a gene that encodes a protein involved in the ribosome, a critical organelle that synthesizes proteins in the cell. The ribosome is composed of a protein called rRNA and a small subunit called A protein. RPL23AP87 is one of the proteins that encodes the A protein, which is a key component of the ribosome.

Recent studies have identified RPL23AP87 as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the biology and potential applications of RPL23AP87 in more detail.

The biology of RPL23AP87

The ribosome is a complex organelle that plays a critical role in protein synthesis. It is composed of a protein called rRNA and a small subunit called A protein. The rRNA provides a framework for the A protein to bind to specific amino acids, while the A protein recognizes and binds to the amino acids, forming the protein sequence.

RPL23AP87 is one of the proteins that encodes the A protein. It is a single-chain protein with 114 amino acid residues. RPL23AP87 is located on chromosome 18q21 and has a calculated molecular weight of 18.5 kDa.

Expression and localization

RPL23AP87 is highly expressed in various tissues and organs, including the brain, heart, muscle, and blood cells. It is also expressed in the liver, kidneys, and pancreas, which are potential targets for RPL23AP87-based therapeutics.

RPL23AP87 is primarily localized to the endoplasmic reticulum (ER), a organelle that transports proteins to the cytoplasm. It is also known to be localized to the nuclear envelope, which is a thin layer of nuclear tissue that surrounds the nucleus.

Drug targeting

RPL23AP87 has been identified as a potential drug target due to its unique biology and expression patterns. Several studies have shown that inhibitors of RPL23AP87 can reduce the formation of protein crystals in cell culture, which is a key step in the development of many diseases.

In addition, RPL23AP87 has been shown to play a role in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It is also involved in the development of certain autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

Biomarker potential

RPL23AP87 has also been identified as a potential biomarker for various diseases. The formation of protein crystals in cell culture is a key step in the development of many diseases, including cancer. Therefore, RPL23AP87 has potential as a biomarker for cancer.

In addition, RPL23AP87 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Therefore, RPL23AP87 may have potential as a biomarker for these diseases as well.

Conclusion

In conclusion, RPL23AP87 is a gene that encodes a protein involved in the ribosome. It is highly expressed in various tissues and organs and has been shown to play a role in the development of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, RPL23AP87 may have potential as a drug target or biomarker

Protein Name: Ribosomal Protein L23a Pseudogene 87

The "RPL23AP87 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPL23AP87 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets